Yang H, et al. - Researchers performed this study on, probably, the largest population to date in order to systematically define the cancer-associated myositis-specific autoantibodies (MSAs) in idiopathic inflammatory myopathies (IIMs). They found that in patients with IIMs, there was an increased risk of cancer in relation to anti-SAE1, and previously reported anti-transcriptional intermediary factor 1-γ and anti-nuclear matrix protein (NXP2), antibodies. Furthermore, anti-HMGCR, anti-Jo-1 and anti-PL-12 antibody production might also be driven by malignancy in some cases.